Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
Open Access
- 1 November 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (11)
- https://doi.org/10.1128/AAC.00590-20
Abstract
Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual post hoc PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen.Funding Information
- Merck Sharp & Dohme Corp.
- Merck Sharp & Dohme Corp.
- Merck Sharp & Dohme Corp.
This publication has 9 references indexed in Scilit:
- Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil FumarateAntimicrobial Agents and Chemotherapy, 2019
- Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
- Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1Antimicrobial Agents and Chemotherapy, 2019
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD TrialClinical Infectious Diseases, 2018
- Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb TrialAntiviral Therapy, 2018
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialThe Lancet HIV, 2018
- Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2017
- Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care PanelAnnals of Internal Medicine, 2012
- Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costsPatient Preference and Adherence, 2011